Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group

FBR Capital Remains Bullish as Prima BioMed (PBMD) Announces Investigator-Sponsored Trial

July 12, 2016 1:47 PM EDT

FBR Capital reiterated an Outperform rating and $6.00 price target on Prima Biomed (NASDAQ: PBMD) following the company's announced collaboration for an investigator-sponsored clinical trial.

Analyst Vernon Bernardino commented, "Earlier today, July 12, Prima BioMed (PBMD) announced a new collaboration for an investigatorsponsored clinical trial named INSIGHT to evaluate intra-tumoral injection of PBMDs immune-oncology therapy,... More